

July 15, 2026

To, National Stock Exchange of India Limited, “Exchange Plaza”, 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex Bandra (East), Mumbai – 400 051	To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
NSE Symbol: GLENMARK	BSE Scrip Code: 532296
ISIN: INE935A01035	ISIN: INE935A01035
Our Reference No. 29/26-27	Our Reference No. 29/26-27

Dear Sir/ Madam,

Sub: Intimation under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”) - Board Meeting to consider and approve the Unaudited Financial Results of Glenmark Pharmaceuticals Limited (“the Company”) for the quarter ended June 30, 2026.

This is to inform you that a meeting of the Board of Directors of the Company will be held on Friday, July 31, 2026, *inter alia*, to consider and approve the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter ended June 30, 2026.

Please note that the notice of the aforesaid meeting is also being made available on the website of the Company in terms of Regulation 46(2) of the SEBI LODR.

Further, the Unaudited Financial Results of the Company shall be submitted to the Stock Exchanges after the conclusion of the aforesaid Board Meeting on Friday, July 31, 2026, and will also be hosted on the website of the Company on the said date and thereafter shall be published in the newspapers, in accordance with the SEBI LODR.

Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, and Company’s Code of Conduct for Prevention of Insider Trading, the Company has already informed the Stock Exchanges vide its letter dated June 25, 2026 that the window for trading in securities of the Company for the Designated Persons viz, Directors, Key Managerial Personnel, Identified Employees / Persons of the Company including the Immediate Relatives of the Designated Persons and the Connected Persons, etc. would remain closed from July 01, 2026 till the expiry of 48 hours after the declaration of Unaudited Financial results for the quarter ended

Glenmark Pharmaceuticals Limited

Glenmark House, B. D. Sawant Marg, Andheri (East), Mumbai 400 099, India

T: +91 22 4018 9999 F: +91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

June 30, 2026 and accordingly, the trading window shall remain closed till Sunday, August 02, 2026 and shall re-open thereafter, i.e. on Monday, August 03, 2026. This is for your information, and you are requested to bring this to the notice of your constituents and take the above information on your record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Rashmi Khandelwal
Company Secretary & Compliance Officer
ACS - 28839